Table 1.
Data sources for efficacy data
| Study | Vaccine | Timeframe postvaccination | Measure/s of effectiveness | Age groups included | Variants analysed | Study type | Country | Data derived from |
|---|---|---|---|---|---|---|---|---|
| Goldberg et al.25 | BNT162b2a | 1.5–6.5 months |
1) PCR positive 2) Severe diseaseb |
16–39 40–59 ≥60 |
Delta | Retrospective cohort study | Israel | Table S7 |
| Chemaitelly et al.10 | BNT162b2 | 0.5 to ≥7 months |
1) PCR positive 2) Hospitalisation (severe disease critical disease and fatal) |
any | Alpha, Betac, Delta | Test-negative case control | Qatar | Table 2 |
| Keehner et al.27 | BNT162b2 or mRNA-1273 | 1–7 months | PCR positive and >1 symptom | ≥18 | Deltad | Retrospective cohort study | USA | Calculated based on attack rates for July given in text |
| Andrews et al.9 |
BNT162b2 ChAdOx1 nCoV-19 mRNA-1273 |
0.5 to ≥9 months |
1) PCR-confirmed symptomatic disease 2) Hospitalisation 3) Death |
≥16 ≥65 40–64 16–39 |
Alpha Delta |
Test-negative case control | England |
Table 1 Table 2 Table S10 Table S11 Table S12 |
| El Sahly et al.24 | mRNA-1273 | 0.5 to ≥8 months |
1) Prevention of illness 2) Prevention of severe disease |
≥18 to <65 ≥65 |
Ancestral | Randomised controlled trial | USA | Supplementary Table S30 |
| Thomas et al.20 | BNT162b2 | 0.25 to ≥4 months | 1) Laboratory-confirmed disease (≥ 1 symptom) | ≥12 | pre-Delta | Randomised controlled trial |
USA Argentina Brazil South Africa Germany Turkey |
Fig. 2 |
| Rosenberg et al.26 |
BNT162b2 mRNA-1273 |
0–8 months |
1) Laboratory-confirmed disease 2) Hospitalisation |
18–49 50– 5 |
pre-Delta Delta |
Prospective cohort study | USA | Tables 2 and 3 |
| Andrews et al.8, 47 |
BNT162b2 ChAdOx1 nCoV-19 mRNA-1273 |
0.5 to ~25 months |
1) PCR-confirmed symptomatic disease 2) Hospitalisation |
≥18 |
Delta Omicron |
Test-negative case control | England | Table 3 |
| Ferdinands et al.22 | mRNA vaccines | 0.5–25 months |
1) PCR-confirmed hospital presentation 2) PCR-confirmed hospital admission |
≥18 |
Delta Omicron |
Test-negative case control | USA | Table 2 |
| Poukka et al.28 |
mRNA vaccines ChAdOx1 nCoV-19 |
0–8 months |
1) Laboratory-confirmed infection 2) Hospitalisation |
16–69 |
pre-Delta Delta |
Retrospective cohort study | Finland | Supplementary Tables 2 and 3 |
| Tseng et al.11 | mRNA-1273 | 0.5–25 months |
1) Infection 2) Hospitalisation |
≥18 |
Delta Omicron |
Test-negative case control | USA | Table 2 |
| Skowronski et al.21 |
BNT162b2ChAdOx1 nCoV -19 mRNA-1273 |
0.5–11.5 months |
1) PCR-positive infection 2) Hospitalisation |
≥18 | Delta | Test-negative case control | Canada | Supplementary Tables 13 and 14 |
| Thompson et al.23 | mRNA vaccines | 0.5–25 months | Hospitalisation | ≥18 |
Delta Omicron |
Test-negative case control | USA | Table 2 |
| Bianchi et al.18 | BNT162b2 | 0.5–5 months |
1) PCR-confirmed infection 2) Symptomatic disease |
21–70 | pre-Delta | Observational cohort study | Italy | Table 3 |
| Katikireddi et al.19 | ChAdOx1 nCoV-19 | 0–5 months |
1) Confirmed symptomatic infection 2) Hospital admissions or death |
≥18 18–64 65–79 ≥80f |
Delta | Retrospective cohort study |
Scotland Brazile |
Tables 2, 3, Table S19 |
aFully vaccinated = 7 days + post second dose.
bSevere disease efficacy included for ages >40 years.
cEffectiveness data against Beta infections were not included in this analysis.
dInfections were >95% Delta in the timeframe analysed.
eOnly effectiveness data from Scotland was used, as this was the only cohort that used an unvaccinated reference cohort.
fEffectiveness data from a cohort comprised exclusively of individuals over 80 years of age was not included in our analysis.